Survival with docetaxel plus capecitabine comparing with vinorelbine plus capecitabine followed by capecitabine maintenance treatment as first-line therapy in patients with advanced breast cancer: A phase III randomized clinical trial

被引：0
|
作者：
Xu, Binghe
Wang, Jiayu
Li, Qing
Zhang, Pin
Yuan, Peng
Ma, Fei
Cai, Ruigang
Fan, Ying
Luo, Yang
Li, Qiao
机构：
[1] Chinese Acad Med Sci, Canc Hosp, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci, Canc Hosp & Inst, Beijing 100730, Peoples R China
[3] Peking Union Med Coll, Beijing 100021, Peoples R China
[4] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Med Oncol, Beijing 100730, Peoples R China
[5] Chinese Acad Med Sci, Canc Hosp, Dept Med Oncol, Beijing 100730, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.1049
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1049
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Capecitabine Combined With Docetaxel Versus Vinorelbine Followed by Capecitabine Maintenance Medication for First-Line Treatment of Patients With Advanced Breast Cancer: Phase 3 Randomized Trial
    Wang, Jiayu
    Xu, Binghe
    Yuan, Peng
    Ma, Fei
    Li, Qing
    Zhang, Pin
    Cai, Ruigang
    Fan, Ying
    Luo, Yang
    Li, Qiao
    CANCER, 2015, 121 (19) : 3412 - 3421
  • [2] First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
    Liang, Xu
    Yan, Ying
    Wang, Lina
    Song, Guohong
    Di, Lijun
    Jiang, Hanfang
    Wang, Chaoying
    Li, Huiping
    ONCOLOGY LETTERS, 2015, 9 (02) : 987 - 993
  • [3] Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer
    Mavroudis, D.
    Papakotoulas, P.
    Ardavanis, A.
    Syrigos, K.
    Kakolyris, S.
    Ziras, N.
    Kouroussis, C.
    Malamos, N.
    Polyzos, A.
    Christophyllakis, C.
    Kentepozidis, N.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2010, 21 (01) : 48 - 54
  • [4] Vinorelbine (V) plus docetaxel (D) followed by Capecitabine (C) as first-line treatment of metastatic breast cancer (MBC)
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 168 - 169
  • [5] Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
    Yu Hong Li
    Hui Yan Luo
    Feng Hua Wang
    Zhi Qiang Wang
    Miao Zhen Qiu
    Yan Xia Shi
    Xiao Juan Xiang
    Xiao Qing Chen
    You Jian He
    Rui Hua Xu
    Journal of Cancer Research and Clinical Oncology, 2010, 136 : 503 - 510
  • [6] Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
    Li, Yu Hong
    Luo, Hui Yan
    Wang, Feng Hua
    Wang, Zhi Qiang
    Qiu, Miao Zhen
    Shi, Yan Xia
    Xiang, Xiao Juan
    Chen, Xiao Qing
    He, You Jian
    Xu, Rui Hua
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (04) : 503 - 510
  • [7] A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
    Yoo, Changhoon
    Kim, Sung-Bae
    Ahn, Jin-Hee
    Kim, Jeong Eun
    Jung, Kyung Hae
    Gong, Gyung-Yub
    Son, Byung-Ho
    Ahn, Sei-Hyun
    Ahn, Seung Do
    Kim, Hak-Hee
    Shin, Hee Jung
    Kim, Woo Kun
    CANCER RESEARCH AND TREATMENT, 2015, 47 (03): : 406 - 415
  • [8] DOCETAXEL PLUS EPIRUBICIN VERSUS DOCETAXEL PLUS CAPECITABINE AS FIRST LINE TREATMENT IN PATIENTS WITH ADVANCED BREAST CANCER. FINAL RESULTS OF A MULTICENTER PHASE III TRIAL
    Mavroudis, D.
    Papakotoulas, P.
    Ardavanis, A.
    Kakolyris, S.
    Kouroussis, C.
    Malamos, N.
    Polyzos, A.
    Christophyllakis, C.
    Kentepozidis, N.
    Geirgoulias, V.
    ANNALS OF ONCOLOGY, 2008, 19 : 63 - 64
  • [9] A randomized controlled Phase II trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer
    Li, Shufen
    Meng, Wenjing
    Zhang, Jibo
    Xie, Xiaojuan
    Hao, Chunfang
    Jia, Yongsheng
    Tong, Zhongsheng
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2020, 16 (05) : 1069 - 1076
  • [10] Docetaxel plus S-1 versus docetaxel plus capecitabine as first-line treatment for advanced breast cancer patients: a prospective randomized phase II study
    Abudureheiyimu, Nilupai
    Wu, Yun
    Li, Qing
    Zhang, Pin
    Ma, Fei
    Yuan, Peng
    Luo, Yang
    Fan, Ying
    Chen, Shanshan
    Cai, Ruigang
    Li, Qiao
    Han, Yiqun
    Xu, Hangcheng
    Wang, Yan
    Wang, Jiayu
    JOURNAL OF THE NATIONAL CANCER CENTER, 2023, 3 (02): : 115 - 120
12345